Penumbra, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. The filing also reports fourth-quarter results; it does not provide formal quarterly or annual financial guidance. Penumbra designs, manufactures and sells medical devices for neurovascular and peripheral vascular procedures, primarily through direct sales.
Financial performance
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Revenue | $333.8 million | $263.3 million | +26.8% |
| Gross profit / margin | $217.1 million / 65.1% | $170.8 million / 64.9% | Margin +0.2 percentage points |
| Operating income (loss) | $1.2 million | ($1.4 million) | Improved by $2.5 million |
| Net income | $4.7 million | $14.8 million | Down $10.2 million |
| Diluted EPS | $0.13 | $0.44 | Down $0.31 |
| Operating cash flow | $12.7 million | ($12.8 million) | Improved by $25.5 million |
- Revenue mix: Neuro revenue was $232.4 million, up 25.3%; peripheral vascular revenue was $101.3 million, up 30.3%. U.S. revenue rose 24.5% to $219.2 million; international revenue rose 31.4% to $114.6 million and represented 34.3% of total sales.
- Costs and margins: R&D expense increased 32.6% to $31.7 million; SG&A increased 24.3% to $184.3 million. SG&A was 55.2% of revenue, versus 56.3% in 2016. Management attributed spending growth mainly to staffing, product development, testing and clinical trials.
- Quarterly trend: Revenue increased through the year, from $73.2 million in Q1 to $96.1 million in Q4. Net income was a loss of $3.1 million in Q1 and $1.6 million in Q2, followed by income of $0.2 million in Q3 and $9.1 million in Q4.
- Cash and liquidity: Year-end cash and cash equivalents were $50.6 million and marketable investments were $164.0 million, compared with $13.2 million and $115.5 million, respectively, in 2016. Working capital was $330.7 million, up from $228.0 million. Management said available liquidity was expected to meet requirements for at least 12 months.
- Cash flow and investment: Operating cash flow turned positive, though inventory growth used $18.8 million of cash and receivables growth used $9.1 million. Investing cash outflow was $77.7 million, including net purchases of investments, $12.5 million of capital expenditures and $9.3 million for the Crossmed acquisition. Financing cash inflow was $104.4 million, including $106.3 million net proceeds from a March 2017 stock offering.
- Debt: The balance sheet reports total liabilities of $76.3 million, but does not present a clear year-end debt balance. The cash flow statement records $1.1 million in payments on debt and credit facilities during 2017.
Changes, outlook and notable items
- Revenue growth was driven by greater market penetration and procedure volumes, including Penumbra System and neuro access sales, and Indigo System sales. Management said product prices were substantially unchanged in both major product categories.
- Net income fell despite higher revenue and a return to operating profit. The 2017 income tax benefit was $3.6 million, versus a $15.7 million benefit in 2016. FY2017 included a $15.4 million tax expense from remeasuring deferred tax assets after the U.S. corporate tax rate reduction, a $2.4 million valuation allowance for federal R&D tax credits, and a $19.8 million Q4 benefit from releasing a valuation allowance. The tax items materially affected reported earnings.
- Penumbra acquired Italian distributor Crossmed in July 2017. The acquisition contributed $6.2 million of revenue and $0.2 million of net income in 2017. Crossmed-related contingent consideration was recorded, with a $2.9 million payment for 2017 milestones due in Q1 2018.
- The company entered an exclusive technology license agreement, recording a $15.2 million indefinite-lived intangible asset and a $12.7 million liability for estimated future milestone payments. Amortization is to begin after regulatory approval to commercialize products using the technology.
- Management expects R&D and SG&A costs to continue increasing as it develops products, expands sales and grows operations. It cautioned that recent market growth rates are not expected to continue at the same pace. No quantified revenue, earnings or margin outlook was given.
- Key risks include strong competition, product and regulatory approval risks, reliance on specialist physician adoption and reimbursement, inventory and single-source supplier exposure, dependence on the Alameda manufacturing campus, distributor concentration (including Japan), foreign exchange exposure without hedging, and execution risks from rapid growth. A medical-device excise tax suspension began in 2018; absent further legislative action, the tax was expected to return in 2020.
- A product-liability case involving Penumbra Coil 400 was settled on confidential terms in November 2017. The filing states that other known litigation was not expected to have a material adverse effect. The auditor gave unqualified opinions on the financial statements and internal controls; the internal-control assessment excluded Crossmed.
Important facts for investors to verify
- How much FY2017 and Q4 earnings depended on tax benefits, valuation-allowance judgments and the Tax Cuts and Jobs Act remeasurement.
- Whether revenue growth and procedure adoption continue, particularly for Penumbra System and Indigo, and whether growth moderates as management expects.
- Whether operating cash flow remains positive as inventory, receivables and commercial expansion consume working capital.
- The timing, regulatory status and commercial prospects of the licensed technology, and the assumptions underlying its $12.7 million milestone liability.
- Crossmed’s integration, future performance-based payments and contribution to international sales; Japan represented 10.1% of FY2017 revenue.
- The year-end debt position, which is not clearly stated as a separate balance-sheet amount in the filing text.